CompletedPhase 3NCT05579327
Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency)
Studying Allan-Herndon-Dudley syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Rare Thyroid Therapeutics International AB
- Principal Investigator
- Andrew J. Bauer, MDChildren's Hospital of Philadelphia
- Intervention
- Tiratricol(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 4 years · MALE
- Timeline
- 2023 – 2025
Study locations (8)
- Rare Disease Research, LLC, Kissimmee, Florida, United States
- Rare Disease Research, LLC, Atlanta, Georgia, United States
- SSM Health Cardinal Glennon Children's Hospital, St Louis, Missouri, United States
- Rare Disease Research, LLC, Hillsborough, North Carolina, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Tranquil Clinical and Research Consulting Services, Webster, Texas, United States
- Erasmus MC, Rotterdam, Netherlands
- Addenbrooke's Hospital, Cambridge, United Kingdom
Collaborators
Premier Research · Egetis Therapeutics
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05579327 on ClinicalTrials.govOther trials for Allan-Herndon-Dudley syndrome
Additional recruiting or active studies for the same condition.